July 02,2021
HANGZHOU HIGHLIGHTLL: TWICE THE TARGET, HOLD THE TOX
Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer compound against the same targets to treat a broad range of autoimmune diseases. Both compounds would need to find a foothold in a crowded marketplace.
Read More